deltatrials
Terminated PHASE2 NCT00596336

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

A Randomized Phase II Trial to Determine Whether the Application of Imiquimod Cream to the Vaccination Site Can Improve the Immune Responsiveness to Influenza Vaccination in Patients With Untreated Chronic Lymphocytic Leukemia

Sponsor: CLL Topics, Inc.

Conditions Chronic Lymphocytic Leukemia
Interventions Imiquimod cream influenza vaccine
Updated 6 times since 2017 Last updated: Apr 11, 2017 Started: Oct 31, 2007 Primary completion: Dec 31, 2011 Completion: Mar 15, 2017

Listed as NCT00596336, this PHASE2 trial focuses on Chronic Lymphocytic Leukemia and remains terminated or withdrawn. Sponsored by CLL Topics, Inc., it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. May 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

▶ Show 1 earlier version

  1. Jan 2017 — May 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CLL Topics, Inc.
  • The Royal Bournemouth Hospital
Data source: The Royal Bournemouth Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bournemouth, United Kingdom